TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03640715

Intervention type: OTHER
Group type: OTHER
Intervention: ENVU
Description: ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.

Intervention type: OTHER
Group type: OTHER
Intervention: ENVU
Description: ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.

Intervention type: OTHER
Group type: OTHER
Intervention: ENVU
Description: ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
Study: NCT02098915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous metoclopramide
Description: the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
Study: NCT01228695

Intervention type: OTHER
Intervention: sleep study
Description: The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
Study: NCT02621008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Reduction& Healthy living
Description: Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
Study: NCT01620437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
Study: NCT03432585

Intervention type: BEHAVIORAL
Intervention: Applicant Survey
Description: This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
Study: NCT01913652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study: NCT01792024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase Thermal Therapy
Description: MR guided laser ablation of prostate cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MR-guided LITT
Study: NCT01959269

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY 73-4506)
Description: As determined by the treating physician
Study: NCT04377399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
Study: NCT03833336

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferroglycine Sulfate
Description: One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrosomial Iron
Description: One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
Study: NCT03385629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSM theory-based didactic education and skills training
Description: Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AAP-based didactic education
Description: American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice EMR changes
Description: Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
Study: NCT04825106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic context
Description: A life-threatening situation occurs in 3 different contexts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic context
Description: A life-threatening situation occurs in 3 different contexts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic context
Description: A life-threatening situation occurs in 3 different contexts
Study: NCT05012514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT RED
Description: Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1.
Study: NCT04711395

Intervention type: DEVICE
Intervention: measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.
Description: subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.

Intervention type: DEVICE
Intervention: measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.
Description: subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
Study: NCT00192465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp.1: 3 mg/kg IV (single dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp. 2: 15 mg/kg IV (single dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp. 3: 30 mg/kg IV (single dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp. 4: 3 mg/kg IM (single dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-524 (Numax-TM)
Description: Grp.5: 3 mg/kg IM (two doses)
Study: NCT02543801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Included as an element of the Liposomal bupivacaine intervention periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Included as an element of the Liposomal bupivacaine intervention periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Included as an element of both interventions as a standard of care periarticular injection
Study: NCT01888991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Preload and Exercise Intervention
Description: A glucose preload and exercise were administered to examine the modulate substrate oxidation
Study: NCT00724126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01436175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Description: SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
Study: NCT02543801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Included as an element of both interventions as a standard of care periarticular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Included as an element of both interventions as a standard of care periarticular injection
Study: NCT01921959

Intervention type: BEHAVIORAL
Intervention: Intervention
Description: Postpartum women are randomized to intervention or control group
Study: NCT04631757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + SOX + Radiotherapy
Description: Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
Study: NCT02450903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750mg once daily
Study: NCT00604539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (Condrosan)
Description: 800 mg (two capsules of 400 mg each) taken once a day for one year
Study: NCT03187626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Study: NCT00604539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
Study: NCT00711711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: relaxation
Description: Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
Study: NCT02279173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim subcutaneous weekly injection
Study: NCT03187626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Study: NCT00603993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
Study: NCT05063669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Occupational Therapy
Description: In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
Study: NCT02045368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-Methotrexate conjugate
Description: IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
Study: NCT06747143

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DN-114001
Description: Probiotic
Study: NCT01941901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Intratumoral injection, once only treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotherapy with bleomycin
Description: Intratumoral injection, once only treatment
Study: NCT03903692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marine polysaccharide dressing
Description: The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose dressing
Description: The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
Study: NCT03339466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle therapy
Description: 6 weeks of inspiratory muscle therapy
Study: NCT02473016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide Drug Delivery System (CDDS)
Description: Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
Study: NCT00290355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 249553 vaccine
Description: Intramuscular injection, 13 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration, 13 doses
Study: NCT03322592

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid on-site evaluation (ROSE)
Description: On-site evaluation of the acquired samples will be performed by pathologist

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Histologic evaluation
Description: Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
Study: NCT06761625

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SanProbi® Barrier capsules
Description: The probiotic group received SanProbi® Barrier capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group received capsules filled mainly with maize starch and maltodextrins.
Study: NCT04070950

Intervention type: OTHER
Intervention: Questionnaires
Description: Two self-questionnaires
Study: NCT02655562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Study: NCT03427762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups.
Study: NCT04535856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic mesenchymal stem cell
Description: Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic mesenchymal stem cell
Description: Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group (placebo)
Study: NCT02124252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based testing with standard linkage to care
Description: Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based HPV testing with enhanced linkage to care
Description: Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.